MX9603259A - Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii. - Google Patents

Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii.

Info

Publication number
MX9603259A
MX9603259A MX9603259A MX9603259A MX9603259A MX 9603259 A MX9603259 A MX 9603259A MX 9603259 A MX9603259 A MX 9603259A MX 9603259 A MX9603259 A MX 9603259A MX 9603259 A MX9603259 A MX 9603259A
Authority
MX
Mexico
Prior art keywords
angiotensin
treatment
antagonists
normotensive glaucoma
glaucoma
Prior art date
Application number
MX9603259A
Other languages
English (en)
Inventor
Alica Huxley
Georg Mathis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX9603259A publication Critical patent/MX9603259A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invencion describe el uso de un antagonista de angiotensina IIo de una sal farmacéuticamente aceptable del mismo en la preparacion de una composicion farmacéutica para el tratamiento de glaucoma por tension normal y procesos neurodegenerativos.
MX9603259A 1994-02-08 1995-01-26 Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii. MX9603259A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810071 1994-02-08
PCT/IB1995/000056 WO1995021609A1 (en) 1994-02-08 1995-01-26 Treatment of normotensive glaucoma with angiotensin ii antagonists

Publications (1)

Publication Number Publication Date
MX9603259A true MX9603259A (es) 1997-03-29

Family

ID=8218203

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9603259A MX9603259A (es) 1994-02-08 1995-01-26 Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii.

Country Status (17)

Country Link
US (1) US5889020A (es)
EP (1) EP0743852B1 (es)
JP (1) JPH09508641A (es)
CN (1) CN1140409A (es)
AT (1) ATE300287T1 (es)
AU (1) AU1423795A (es)
CA (1) CA2181461A1 (es)
CY (1) CY2567B1 (es)
DE (1) DE69534339T2 (es)
DK (1) DK0743852T3 (es)
ES (1) ES2243933T3 (es)
FI (1) FI963083A (es)
IL (1) IL112520A0 (es)
MX (1) MX9603259A (es)
NO (1) NO963064D0 (es)
WO (1) WO1995021609A1 (es)
ZA (1) ZA95958B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
WO1995024902A1 (fr) * 1994-03-16 1995-09-21 Sankyo Company, Limited Reducteur de tension oculaire
JPH10167961A (ja) * 1996-12-11 1998-06-23 Santen Pharmaceut Co Ltd 緑内障治療剤
EP1870098A3 (en) * 1998-07-10 2010-07-07 Novartis Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
PT1197223E (pt) 1999-04-28 2005-04-29 Takeda Pharmaceutical Preventivos/medicamentos/inibidores da progressao de retinopatia simples ou retinopatia pre-proliferativa
CN1198650C (zh) * 1999-06-11 2005-04-27 三共株式会社 局部给药用眼压降低组合物
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
EP1224945A4 (en) * 1999-10-25 2004-08-18 Senju Pharma Co MEANS TO RELEASE THE CELLARIAN TENSION
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
HUP0301057A3 (en) 2000-02-18 2004-01-28 Takeda Pharmaceutical Angiotenzin ii antagonist heterocyclic compound an their use for preparation of tnf-alpha inhibitors
WO2002045748A1 (fr) * 2000-12-05 2002-06-13 Sankyo Company, Limited Compositions d'abaissement de la tension oculaire pour administration topique
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
CA2522318C (en) * 2003-04-15 2011-09-13 Sankyo Company Limited Drug for preventing or treating angiogenic eye diseases
PL1750862T3 (pl) * 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
PT1872783E (pt) * 2005-04-21 2012-01-16 Santen Pharmaceutical Co Ltd Agente terapêutico para distúrbio queratoconjuntivo
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
PT2376101E (pt) * 2008-12-29 2016-02-04 Trevena Inc Efectores da beta-arrestina e composições e métodos para a sua utilização
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
EP3102223A4 (en) 2014-02-07 2017-11-29 Trevena, Inc. Crystalline and amorphous forms of a beta-arrestin effector
US9611293B2 (en) 2014-05-19 2017-04-04 Trevena, Inc. Synthesis of beta-arrestin effectors
CN105188250A (zh) * 2015-09-09 2015-12-23 上海联影医疗科技有限公司 靶组件以及具有该靶组件的直线加速器
CN105244434B (zh) * 2015-10-13 2017-10-10 北京科技大学 一种C掺杂ZnO热电材料的制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03223281A (ja) * 1989-12-01 1991-10-02 Glaxo Group Ltd ベンゾチオフェン誘導体
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma

Also Published As

Publication number Publication date
IL112520A0 (en) 1995-05-26
ZA95958B (en) 1995-08-08
NO963064L (no) 1996-07-23
AU1423795A (en) 1995-08-29
CA2181461A1 (en) 1995-08-17
NO963064D0 (no) 1996-07-23
CN1140409A (zh) 1997-01-15
CY2567B1 (en) 2008-07-02
DE69534339D1 (de) 2005-09-01
ATE300287T1 (de) 2005-08-15
DE69534339T2 (de) 2006-05-24
EP0743852A1 (en) 1996-11-27
JPH09508641A (ja) 1997-09-02
DK0743852T3 (da) 2005-10-17
WO1995021609A1 (en) 1995-08-17
ES2243933T3 (es) 2005-12-01
FI963083A (fi) 1996-08-07
FI963083A0 (fi) 1996-08-05
EP0743852B1 (en) 2005-07-27
US5889020A (en) 1999-03-30

Similar Documents

Publication Publication Date Title
MX9603259A (es) Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii.
GR3036881T3 (en) Benzamide derivatives and their use as vasopressin antagonists
NZ332780A (en) Substituted amines for the treatment of neurological and neuropsychiatric disorders
HUT70441A (en) Substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin ii receptor antagonist properties and pharmaceutical compositions comprising them
NO317747B1 (no) Farmasoytisk preparat samt anvendelse derav
EP0750909A4 (en) USE OF AMINO-HYDROGENATED CHINAZOLINE COMPOUNDS AND THEIR DERIVATIVES FOR BODYING IN DRUG ADDICTION
CA2217513A1 (en) Pharmaceutical agents for the treatment of alzheimer's disease
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
HU9600766D0 (en) Use of cgrp antagonist for the treatment of pruritus and ocular or palpebral dysaesthesias
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
HU9701060D0 (en) Pharmaceutical composition for treating cognitive disturbs
HUT75115A (en) Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade
GR3035676T3 (en) Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical composition
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
EP0797995A3 (en) Use of a 5-HT2 receptor antagonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis
IL123536A0 (en) 5-HT3 Receptor antagonists for dyskinesia
CA2228572A1 (en) Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
SI0815126T1 (en) Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical composition
AP9600780A0 (en) Process for the preparation of peroxetine hydrochloride anhydrate and its use as therapeutic agent.